Scoop has an Ethical Paywall
Vertex Announces Funding Application For Trikafta® Has Been Made To PHARMAC
Vertex is pleased to confirm that a funding application for Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) has been made to PHARMAC.
This follows our recent submission earlier in June to Medsafe for the evaluation of Trikafta for the treatment of cystic fibrosis (CF) in people ages 6 years and older. Medsafe granted priority review for the submission, which could see the review time for the evaluation significantly reduced. PHARMAC previously agreed to review this funding application in parallel to the Medsafe review.
Vertex is willing to work collaboratively and flexibly with PHARMAC and we look forward to dialogue and the next steps in the process.
Vertex has made significant progress in New Zealand over the last few months and is committed to ensuring all eligible patients have sustainable access to our triple combination treatment as soon as possible.
Note: Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is not a registered product in New Zealand and this statement is for information purposes only.
NIWA: Students Representing New Zealand At The ‘Olympics Of Science Fairs’ Forging Pathway For International Recognition
Coalition to End Big Dairy: Activists Protest NZ National Dairy Industry Awards Again
Infoblox: Dancing With Scammers - The Telegram Tango Investigation
Consumer NZ: This Mother’s Day, Give The Gift Of Scam Protection And Digital Confidence
NZ Airports Association: Airlines And Airports Back Visa Simplification
Netsafe: Statement From Netsafe About Proposed Social Media Ban